All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
How do 4-year results from the BE SURE and BE BRIGHT trials of bimekizumab impact treatment selection for psoriatic disease?
By Ella Dixon
Featured
Following a recent rheumatology congress, the PsOPsA Hub was pleased to speak with Paolo Gisondi, University Hospital of Verona, Verona, IT. We asked, How do 4-year results from the BE SURE and BE BRIGHT trials of bimekizumab impact treatment selection for psoriatic disease?
4-year results from the BE SURE and BE BRIGHT trials of bimekizumab
Gisondi begins by discussing 4-year PASI response, why these data are clinically relevant, and how the long-term response compares to other treatments. Gisondi then speaks about the safety data from BE SURE and BE BRIGHT, and why safety is key in patients with psoriasis.
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox